Abstract
Alcohol’s impact on telomere length, a proposed marker of biological age, is unclear. We performed the largest observational study to date and compared findings with Mendelian randomization (MR) estimates. Two-sample MR used data from a recent genome-wide association study (GWAS) of telomere length. Genetic variants were selected on the basis of associations with alcohol consumption and alcohol use disorder (AUD). Non-linear MR employed UK Biobank individual data. MR analyses suggest a causal relationship between alcohol and telomere length: both genetically predicted alcohol traits were inversely associated with telomere length. 1 S.D. higher genetically-predicted log-transformed alcoholic drinks weekly had a -0.07 S.D. effect on telomere length (95% confidence interval [CI]:-0.14 to -0.01); genetically-predicted AUD - 0.06 S.D. effect (CI:-0.10 to -0.02). Results were consistent across methods and independent from smoking. Non-linear analyses indicated a potential threshold relationship between alcohol and telomere length. Our findings have implications for potential aging-related disease prevention strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AT is supported by a Wellcome Trust fellowship (216462/Z/19/Z). KPE is funded by the UK Medical Research Council (G1001354 & MR/K013351/1) and the European Commission (Horizon 2020 732592). SB is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). This work was also supported by the Li Ka Shing Centre for Health Information and Discovery, NIH grant (TN: R01EB026859), the National Institute for Health Research Cambridge Biomedical Research Centre (BRC-1215-20014), and a Wellcome Trust award (TN: 100309/Z/12/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UKB approval was obtained from the North West Multi-Centre Research Ethics Committee and the Patient Information Advisory Group. The UKB Board and Access Sub-Committee and the Biobank Ethics and Governance Council reviewed our data access application.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: AT is supported by a Wellcome Trust fellowship (216462/Z/19/Z). KPE is funded by the UK Medical Research Council (G1001354 & MR/K013351/1) and the European Commission (Horizon 2020 732592). SB is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). This work was also supported by the Li Ka Shing Centre for Health Information and Discovery, NIH grant (TN: R01EB026859), the National Institute for Health Research Cambridge Biomedical Research Centre (BRC-1215-20014), and a Wellcome Trust award (TN: 100309/Z/12/Z).
Data Availability
Data is available on successful application to the UK Biobank.
